Skip to main navigation

Life sciences: the pulse of innovation - Ernst & Young - United Kingdom

  • Share

Life sciences: the pulse of innovation

Life sciences companies — from emerging to multinational — are facing challenging times as stakeholder expectations are changing, development pipelines are declining and access to healthcare takes on new importance. Success requires flexible strategies and innovative business models.

Ernst & Young’s Global Life Sciences Center brings together a worldwide team of professionals to help you achieve your potential — a team with deep technical experience in providing assurance, tax, transaction and advisory services.

Whether it’s forming the right alliances, improving operations, exploring new markets or gaining industry insights, we can help you execute for success in today’s complex, competitive and risk-driven environment.

Biotechnology

Biotechnology

Biotech companies are delivering new levels of health, prosperity and sustainability across the world.

Pharmaceutical

Pharmaceutical

Key drivers are reshaping the pharmaceutical marketplace, including the growing power of healthcare payers, providers and evolving customer needs.

Medical Technology

Medical technology

Fundamental drivers in the global healthcare economy suggest demand for medical technology products should be robust for years to come.

Medical technology report 2011

Facing a confluence of risks — increasing regulatory, pricing and financing pressures, uncertain public policy climate and rapidly changing customer base — can medtech find new ways to sustain innovation? We explore. 

Implementing the medical device excise tax

A 2.3% US excise tax on the sale, lease, rental or use of certain med devices goes into effect 1 January 2013. Is your company ready?

Pulse: medical technology report 2012

New technologies are blurring the lines between medical devices, diagnostics and health IT, with the potential to revolutionize health care. Will your company be ready?

Cash on the prescription 2012

In 2011, Big Pharma reported weaker working capital performance compared with 2010. Pressured to improve shareholder value, what measures can companies undertake to restore performance?

Beyond borders: global biotech report 2012

As serious resource constraints continue to plague the industry, how can biotech innovation be sustained? Delve into our 26th edition for key findings and insights.

Progressions 2012: health care everywhere

Disruptive innovations and unsustainable costs are propelling life sciences companies into the behavioral change business. Learn why in our annual life sciences report.

What Europe has to offer biotechnology companies

Europe has the potential to be a world leader in biotechnology, but more needs to be done by industry and regulatory authorities to get there.

Progressions 2011: Building Pharma 3.0

A transformation of the pharmaceutical industry is underway as companies begin shifting from producing new medicines to demonstrating improved health outcomes. No longer the dominant health care player, pharma has a new focus. We report on pharma’s progress in creating new business models and partnerships focused on technology and sustainability.

Life Sciences

News

Events

Contacts

Contact the global life sciences center

Pulse: medical technology report 2012
finger pointing at digital chart
New technologies are blurring the lines between medical devices, diagnostics and health IT, with the potential to revolutionize health care. Will your company be ready? 

Couple061912
Beyond borders: global biotech report 2012
As serious resource constraints continue to plague the industry, how can biotech innovation be sustained? Delve into our 26th edition for key findings and insights.

Watch the Pharma 3.0 webcast 1 minute recap

Webcast: Pharma 3.0: meeting the challenge 
View a recap of our latest Pharma 3.0 discussion. Can your life sciences company improve its communications with payers and practitioners?

Back to top